Cervical screening for women unprotected by HPV herd effect
Part of Cancer, Women’s health & pregnancy clinical trials.
This study checks how well cervical screening works for certain unvaccinated women depending on whether they are protected by “herd effect” from HPV vaccination in the community. It may help improve screening plans for women who may be at higher risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were born between 1995 and 1997
- You have lived for 25 years in one of the study communities
- Your community is classified as either “herd effect protected” or “no herd effect” based on local vaccination coverage
- You have not had immune system–weakening health conditions such as a transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental vaccine (RG002) for women with cervical pre-cancer caused by HPV types 16 or 18. The vaccine is designed to help the body fight the virus and potentially clear the pre-cancerous cells, possibly avoiding more invasive treatments.
This study looks at ways to improve cervical cancer screening for women. If you join, you may help researchers find better methods for early detection, which can lead to earlier treatment and better outcomes.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
This study looks at giving the HPV vaccine (Gardasil 9) to women while they go through Sweden’s routine HPV screening. It helps researchers understand how vaccine use alongside screening affects HPV infection and cervical cancer prevention.
This study looks at whether getting the HPV vaccine along with regular cervical cancer screening (using an HPV test) can help prevent cervical cancer in women living with HIV. It is designed to be done as part of your usual HIV clinic visits, making it easier for you to take part.
This trial tests a new, affordable way to screen for cervical cancer that can be done in low- and middle-income countries. It uses artificial intelligence to help decide who needs follow-up care.
Hear when a new Cervical Intraepithelial Neoplasia Grade 2/3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.